Transcriptional mediators of treatment resistance in lethal prostate cancer

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors(1). Cellular programs driving resistance in both cancer and immune cells remain poor...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Meng Xiao, Cuoco, Michael S., Crowdis, Jett, Bosma-Moody, Alice, Zhang, Zhenwei, Bi, Kevin, Kanodia, Abhay, Su, Mei-Ju, Ku, Sheng-Yu, Garcia, Maria Mica, Sweet, Amalia R., Rodman, Christopher, DelloStritto, Laura, Silver, Rebecca, Steinharter, John, Shah, Parin, Izar, Benjamin, Walk, Nathan C., Burke, Kelly P., Bakouny, Ziad, Tewari, Alok K., Liu, David, Camp, Sabrina Y., Vokes, Natalie I., Salari, Keyan, Park, Jihye, Vigneau, Sébastien, Fong, Lawrence, Russo, Joshua W., Yuan, Xin, Balk, Steven P., Beltran, Himisha, Rozenblatt-Rosen, Orit, Regev, Aviv, Rotem, Asaf, Taplin, Mary-Ellen, Van Allen, Eliezer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960507/
https://www.ncbi.nlm.nih.gov/pubmed/33664492
http://dx.doi.org/10.1038/s41591-021-01244-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960507/
https://www.ncbi.nlm.nih.gov/pubmed/33664492
http://dx.doi.org/10.1038/s41591-021-01244-6

Ejemplares similares